ORYZON reports financial results and corporate update for half-year ending June 30, 2024 01/08/2024 Healthcare Access to innovation Innovative drugs Advanced therapies Research and development (R&D) expenses of $4.9m for the half-year ending June 30, 2024. As a result of the completion... Partners - Oryzon Genomics
Integra Therapeutics to receive up to €10.5 million from European Commission for its FiCAT... 17/07/2024 Healthcare Access to innovation Rare diseases Advanced therapies EU projects This funding will enable Integra Therapeutics to launch its first gene therapy to treat a serious pediatric hepatic... Partners - Integra Therapeutics S.L.
Oryzon announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb ... 26/06/2024 Healthcare Access to innovation Rare diseases Advanced therapies Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre. Partners - Oryzon Genomics
Use of biotechnology in advanced therapies and new technologies in the spanish market 03/06/2024 Healthcare Access to innovation Advanced therapies Among the most important emerging technologies are the manipulation of the microbiota, CAR-T cell therapies, and gene... Partners - KONEXIO BIOTECH
Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for... 24/05/2024 Healthcare Access to innovation Innovative drugs Advanced therapies it is a medicine to improve progression-free survival and overall survival in patients with metastatic pancreatic... Partners
Cellab CDMO obtains a GMP certification for advanced therapy product manufacturing 22/05/2024 Healthcare Access to innovation Personalized medicine Advanced therapies The Spanish Agency for Medicines and Health Products (AEMPS) has certified compliance with the European Union Good... Partners - Cellab
Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate... 21/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies ApTOLL shows potential for slowing the progression of multiple sclerosis (MS) in preclinical animal studies. Partners - AptaTargets
#NewAseBioMember | “This partnership gives us the possibility to establish key contacts an... 20/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies Meet Kirsch Pharma, our new member. We talked to its Raquel Márquez Duro, Key Account Mánager de España y Portugal. AseBio - Kirsch Pharma España
#AseBioID24 | “Being present at Investor Day gives you wings to visualize, work and promot... 08/05/2024 Healthcare Access to innovation Advanced therapies Financing Hector Olabegogeaskoetxea Narbaiza, CEO of MONDRAGON Health, Silver Sponsor of AseBio Investor Day, analyzes the biotech... AseBio
